Heron Therapeutics (HRTX)

May 7, 2025, 3:38 PM EDT - 6 days ago

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

May 6, 2025, 11:38 AM EDT - 7 days ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:45 AM EDT - 8 days ago

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

May 6, 2025, 7:30 AM EDT - 8 days ago

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Apr 28, 2025, 6:55 PM EDT - 15 days ago

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Apr 22, 2025, 4:05 PM EDT - 21 days ago

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Feb 27, 2025, 12:07 PM EST - 2 months ago

Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:45 AM EST - 2 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Feb 13, 2025, 4:20 PM EST - 3 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Dec 23, 2024, 4:05 PM EST - 5 months ago

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Dec 4, 2024, 3:01 PM EST - 5 months ago

Relief For Heron Therapeutics After The Court Win On Cinvanti

Dec 3, 2024, 4:36 PM EST - 5 months ago

U.S. District Court Upholds Validity of CINVANTI® Patents

Nov 12, 2024, 11:45 AM EST - 6 months ago

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:55 AM EST - 6 months ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Nov 4, 2024, 5:00 PM EST - 6 months ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Oct 29, 2024, 4:05 PM EDT - 7 months ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Oct 10, 2024, 4:08 PM EDT - 7 months ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Sep 25, 2024, 8:00 AM EDT - 8 months ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Sep 3, 2024, 8:00 AM EDT - 9 months ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Aug 9, 2024, 10:14 AM EDT - 9 months ago

Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 10 months ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Jul 30, 2024, 4:05 PM EDT - 10 months ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Jul 15, 2024, 8:00 AM EDT - 10 months ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Jul 2, 2024, 8:00 AM EDT - 11 months ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

May 29, 2024, 8:05 AM EDT - 1 year ago

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

May 7, 2024, 2:38 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 16, 2024, 4:24 PM EDT - 1 year ago

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 11, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 12, 2024, 10:35 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Feb 28, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Feb 17, 2024, 1:54 AM EST - 1 year ago

Heron Therapeutics Is Out Of Survival Mode

Jan 23, 2024, 8:00 PM EST - 1 year ago

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Jan 7, 2024, 5:00 PM EST - 1 year ago

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Dec 29, 2023, 3:14 PM EST - 1 year ago

Heron Therapeutics Gets Back On Track

Nov 30, 2023, 9:00 AM EST - 1 year ago

Why Heron Therapeutics Is A Compelling Buy Into 2024

Nov 14, 2023, 7:45 PM EST - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Nov 7, 2023, 4:05 PM EST - 1 year ago

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023

Aug 14, 2023, 6:48 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 7, 2023, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

Jul 28, 2023, 3:57 PM EDT - 1 year ago

Heron Therapeutics: Restructuring Brings About A New Dawn

Jul 24, 2023, 9:02 AM EDT - 1 year ago

Heron Therapeutics Announces Cost Reduction Plan and Restructuring

Jul 24, 2023, 9:00 AM EDT - 1 year ago

Heron Therapeutics Announces $30 Million Private Placement Financing

HTGC

Jun 23, 2023, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Jun 12, 2023, 9:00 AM EDT - 2 years ago

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer